Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
Alkermes and Avadel complete strategic integration in the sleep medication market
The completion of the transaction between Alkermes PLC and Avadel Pharmaceuticals plc marks a significant milestone in the specialized pharmaceutical landscape. This corporate merger represents an important consolidation of forces in the sleep disorder treatment segment, an area that is growing as global demand for innovative sleep health solutions increases.
Expansion of product portfolio and accumulated expertise
With this integration finalized, Alkermes now has access to Avadel Pharmaceuticals’ robust portfolio, especially in medications targeting insomnia and other sleep-related disorders. The synergy between the two organizations allows for a strategic combination of technical knowledge and research and development capabilities. The expanded access to Avadel’s portfolio provides Alkermes with a solid foundation to deepen its presence in the specialized neuropsychiatry market, where sleep treatments are becoming increasingly relevant.
New avenues for growth and innovation
This transaction paves the way for development opportunities that previously seemed distant. Alkermes is now positioned to explore emerging markets and expand its presence in therapies related to sleep disorders. This strategic move not only consolidates the company’s position in the specialized drug segment but also sets the stage for future innovations that could benefit patients with unmet needs in the pharmaceutical market.